Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995 (Sandostatin®)

  • H.-J. Quabbe
  • U. Plöckinger
Conference paper


The long-acting somatostatin analogue SMS 201–995 (Sandostatin®) has recently been introduced for the treatment of acromegaly [1]. We have evaluated its efficacy and long-term usefulness in 12 patients with therapy-resistant disease. All had been previously treated by transsphenoidal surgery, irradiation, bromocriptine or a combination of these but their GH concentrations had been insufficiently lowered. Duration of Sandostatin treatment was at least 12 months in all patients.


Growth Hormone Transsphenoidal Surgery Growth Hormone Concentration Lower Growth Hormone Growth Hormone Suppression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140Google Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1988

Authors and Affiliations

  • H.-J. Quabbe
    • 1
  • U. Plöckinger
    • 1
  1. 1.Department of Internal Medicine, Section of Endocrinology, Klinikum SteglitzFreie UniversitätGermany

Personalised recommendations